Io Biotech, Inc. (IOBT)

$1.48

+0.01

(+0.68%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Io Biotech, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.4% return, outperforming this stock by 71.3%

Performance

  • $1.42
    $1.56
    $1.48
    downward going graph

    4.05%

    Downside

    Day's Volatility :8.97%

    Upside

    5.13%

    downward going graph
  • $0.82
    $2.64
    $1.48
    downward going graph

    44.84%

    Downside

    52 Weeks Volatility :69.08%

    Upside

    43.94%

    downward going graph

Returns

PeriodIo Biotech, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-17.78%
-0.4%
0.0%
6 Months
43.69%
8.5%
0.0%
1 Year
-22.92%
4.2%
-1.2%
3 Years
-90.54%
13.9%
-19.2%

Highlights

Market Capitalization
96.8M
Book Value
$2.02
Earnings Per Share (EPS)
-1.98
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-37.78%
Return On Equity TTM
-63.29%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-91.2M
Diluted Eps TTM
-1.98
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.35
EPS Estimate Next Year
-1.3
EPS Estimate Current Quarter
-0.39
EPS Estimate Next Quarter
-0.36

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Io Biotech, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 440.54%

Current $1.48
Target $8.00

Technicals Summary

Sell

Neutral

Buy

Io Biotech, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Io Biotech, Inc.
Io Biotech, Inc.
-7.5%
43.69%
-22.92%
-90.54%
-90.54%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Io Biotech, Inc.
Io Biotech, Inc.
NA
NA
NA
-1.35
-0.63
-0.38
NA
2.02
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Io Biotech, Inc.
Io Biotech, Inc.
Buy
$96.8M
-90.54%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • Vivo Capital, LLC

    9.37%
  • Novo A/S

    8.72%
  • Samsara BioCapital, LLC

    5.53%
  • Morgan Stanley - Brokerage Accounts

    3.46%
  • Marshall Wace Asset Management Ltd

    3.20%
  • Armistice Capital, LLC

    2.92%

Corporate Announcements

  • Io Biotech, Inc. Earnings

    Io Biotech, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

io biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of t cells that are specific for immune inhibitory molecules. io biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting ido and pd-l1 in clinical development and several compounds finalizing preclinical phase. io biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

Organization
Io Biotech, Inc.
Employees
68
CEO
Dr. Mai-Britt Zocca Ph.D.
Industry
Services

FAQs